CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review)

Safaee,Michael; Clark,Aaron  J.; Ivan,Michael  E.; Oh,Michael  C.; Bloch,Orin; Sun,Matthew  Z.; Oh,Taemin; Parsa,Andrew  T.

doi:10.3892/ijo.2013.2075

CD97 is a multifunctional leukocyte receptor with distinct roles in human cancers (Review)

Authors:
- Michael Safaee
- Aaron J. Clark
- Michael E. Ivan
- Michael C. Oh
- Orin Bloch
- Matthew Z. Sun
- Taemin Oh
- Andrew T. Parsa
View Affiliations

Affiliations: Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA, Department of Neurological Surgery, University of California, San Francisco, CA 94117, USA
Published online on: August 22, 2013 https://doi.org/10.3892/ijo.2013.2075
Pages: 1343-1350

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

G-protein coupled receptors (GPCRs) represent the most diverse and biologically ubiquitous protein receptors. The epidermal growth factor seven-span transmembrane (EGF-TM7) family consists of adhesion GPCRs with a diverse functional repertoire. CD97 is the most broadly expressed member with roles in cell adhesion, migration and regulation of intercellular junctions. CD97 is also expressed in a variety of human malignancies including those of the thyroid, stomach, colon and brain. CD97 confers an invasive phenotype and has been shown to correlate with tumor grade, lymph node invasion, metastatic spread and overall prognosis. More recently, CD97 was found to signal through Gα12/13, resulting in increased RHO-GTP levels. Proven roles in tumor invasion and signaling make CD97 an exciting novel therapeutic target. In this review, we will discuss the structure and function of this receptor, with a specific focus on its mechanistic significance in neoplastic diseases.

View Figures

View References

1.	Yona S, Lin HH, Siu WO, Gordon S and Stacey M: Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci. 33:491–500. 2008. View Article : Google Scholar : PubMed/NCBI
2.	Stacey M, Chang GW, Davies JQ, et al: The epidermal growth factor-like domains of the human EMR2 receptor mediate cell attachment through chondroitin sulfate glycosaminoglycans. Blood. 102:2916–2924. 2003. View Article : Google Scholar
3.	Yona S, Lin HH, Dri P, et al: Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function. FASEB J. 22:741–751. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Kwakkenbos MJ, Pouwels W, Matmati M, et al: Expression of the largest CD97 and EMR2 isoforms on leukocytes facilitates a specific interaction with chondroitin sulfate on B cells. J Leukoc Biol. 77:112–119. 2005.PubMed/NCBI
5.	Chang GW, Davies JQ, Stacey M, et al: CD312, the human adhesion-GPCR EMR2, is differentially expressed during differentiation, maturation, and activation of myeloid cells. Biochem Biophy Res Commun. 353:133–138. 2007. View Article : Google Scholar
6.	Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC and Tak PP: Expression of the activation antigen CD97 and its ligand CD55 in rheumatoid synovial tissue. Arthritis Rheum. 42:650–658. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Matmati M, Pouwels W, van Bruggen R, et al: The human EGF-TM7 receptor EMR3 is a marker for mature granulocytes. J Leukoc Biol. 81:440–448. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Leemans JC, te Velde AA, Florquin S, et al: The epidermal growth factor-seven transmembrane (EGF-TM7) receptor CD97 is required for neutrophil migration and host defense. J Immunol. 172:1125–1131. 2004. View Article : Google Scholar : PubMed/NCBI
9.	van Pel M, Hagoort H, Kwakkenbos MJ, Hamann J and Fibbe WE: Differential role of CD97 in interleukin-8-induced and granulocyte-colony stimulating factor-induced hematopoietic stem and progenitor cell mobilization. Haematologica. 93:601–604. 2008.PubMed/NCBI
10.	Eichler W, Hamann J and Aust G: Expression characteristics of the human CD97 antigen. Tissue Antigens. 50:429–438. 1997. View Article : Google Scholar : PubMed/NCBI
11.	Hamann J, Vogel B, van Schijndel GM and van Lier RA: The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med. 184:1185–1189. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Hamann J, Stortelers C, Kiss-Toth E, Vogel B, Eichler W and van Lier RA: Characterization of the CD55 (DAF)-binding site on the seven-span transmembrane receptor CD97. Eur J Immunol. 28:1701–1707. 1998. View Article : Google Scholar : PubMed/NCBI
13.	Qian YM, Haino M, Kelly K and Song WC: Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55). Immunology. 98:303–311. 1999. View Article : Google Scholar : PubMed/NCBI
14.	Wang T, Ward Y, Tian L, et al: CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood. 105:2836–2844. 2005. View Article : Google Scholar
15.	Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF and McCarty JH: Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res. 71:6371–6381. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Friedlander DR, Zagzag D, Shiff B, et al: Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res. 56:1939–1947. 1996.
17.	Schrappe M, Klier FG, Spiro RC, Waltz TA, Reisfeld RA and Gladson CL: Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. Cancer Res. 51:4986–4993. 1991.
18.	Chang GW, Stacey M, Kwakkenbos MJ, Hamann J, Gordon S and Lin HH: Proteolytic cleavage of the EMR2 receptor requires both the extracellular stalk and the GPS motif. FEBS Lett. 547:145–150. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Qian F, Boletta A, Bhunia AK, et al: Cleavage of polycystin-1 requires the receptor for egg jelly domain and is disrupted by human autosomal-dominant polycystic kidney disease 1-associated mutations. Proc Natl Acad Sci USA. 99:16981–16986. 2002. View Article : Google Scholar : PubMed/NCBI
20.	Krasnoperov V, Lu Y, Buryanovsky L, Neubert TA, Ichtchenko K and Petrenko AG: Post-translational proteolytic processing of the calcium-independent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled receptor. Role of the G protein-coupled receptor proteolysis site (GPS) motif. J Biol Chem. 277:46518–46526. 2002. View Article : Google Scholar
21.	Davies JQ, Chang GW, Yona S, Gordon S, Stacey M and Lin HH: The role of receptor oligomerization in modulating the expression and function of leukocyte adhesion-G protein-coupled receptors. J Biol Chem. 282:27343–27353. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Lin HH, Chang GW, Davies JQ, Stacey M, Harris J and Gordon S: Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G protein-coupled receptor proteolytic site motif. J Biol Chem. 279:31823–31832. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Galle J, Sittig D, Hanisch I, et al: Individual cell-based models of tumor-environment interactions: multiple effects of CD97 on tumor invasion. Am J Pathol. 169:1802–1811. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Davies JQ, Lin HH, Stacey M, et al: Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. Oncol Rep. 25:619–627. 2011.PubMed/NCBI
25.	Aust G, Eichler W, Laue S, et al: CD97: a dedifferentiation marker in human thyroid carcinomas. Cancer Res. 57:1798–1806. 1997.PubMed/NCBI
26.	Aust G, Steinert M, Schutz A, et al: CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am J Clin Pathol. 118:699–707. 2002. View Article : Google Scholar : PubMed/NCBI
27.	Liu Y, Chen L, Peng SY, Chen ZX and Hoang-Vu C: Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. J Zhejiang Univ Sci B. 6:913–918. 2005. View Article : Google Scholar : PubMed/NCBI
28.	Steinert M, Wobus M, Boltze C, et al: Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am J Pathol. 161:1657–1667. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Boltze C, Schneider-Stock R, Aust G, et al: CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathology Int. 52:83–88. 2002. View Article : Google Scholar
30.	Rutkowski MJ, Sughrue ME, Kane AJ, Kim JM, Bloch O and Parsa AT: Epidermal growth factor module-containing mucin-like receptor 2 is a newly identified adhesion G protein-coupled receptor associated with poor overall survival and an invasive phenotype in glioblastoma. J Neurooncol. 105:165–171. 2011. View Article : Google Scholar
31.	Kane AJ, Sughrue ME, Rutkowski MJ, Phillips JJ and Parsa AT: EMR-3: a potential mediator of invasive phenotypic variation in glioblastoma and novel therapeutic target. Neuroreport. 21:1018–1022. 2010. View Article : Google Scholar : PubMed/NCBI
32.	Chidambaram A, Fillmore HL, Van Meter TE, Dumur CI and Broaddus WC: Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness. J Neurosurg. 116:843–853. 2012. View Article : Google Scholar : PubMed/NCBI
33.	Ward Y, Lake R and Martin PL: et al CD97 amplifies LPA receptor signaling and promotes thyroid cancer progression in a mouse model. Oncogene. 32:2726–2738. 2013. View Article : Google Scholar : PubMed/NCBI
34.	Liu D, Trojanowicz B, Ye L, et al: The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma. PLoS One. 7:e399892012. View Article : Google Scholar : PubMed/NCBI
35.	Ward Y, Lake R, Yin JJ, et al: LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res. 71:7301–7311. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Hamann J, Eichler W, Hamann D, et al: Expression cloning and chromosomal mapping of the leukocyte activation antigen CD97, a new seven-span transmembrane molecule of the secretion receptor superfamily with an unusual extracellular domain. J Immunol. 155:1942–1950. 1995.
37.	Gray JX, Haino M, Roth MJ, et al: CD97 is a processed, seven-transmembrane, heterodimeric receptor associated with inflammation. J Immunol. 157:5438–5447. 1996.PubMed/NCBI
38.	Rao Z, Handford P, Mayhew M, Knott V, Brownlee GG and Stuart D: The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell. 82:131–141. 1995.
39.	D’Souza SE, Ginsberg MH and Plow EF: Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem Sci. 16:246–250. 1991.PubMed/NCBI
40.	Hamann J, Hartmann E and van Lier RA: Structure of the human CD97 gene: exon shuffling has generated a new type of seven-span transmembrane molecule related to the secretin receptor superfamily. Genomics. 32:144–147. 1996. View Article : Google Scholar : PubMed/NCBI
41.	Doolittle RF: Stein and Moore Award address. Reconstructing history with amino acid sequences. Protein Sci. 1:191–200. 1992. View Article : Google Scholar : PubMed/NCBI
42.	Bjarnadottir TK, Geirardsdottir K, Ingemansson M, Mirza MA, Fredriksson R and Schioth HB: Identification of novel splice variants of adhesion G protein-coupled receptors. Gene. 387:38–48. 2007. View Article : Google Scholar : PubMed/NCBI
43.	Lin HH, Stacey M, Saxby C, et al: Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions: dissection of the CD97-CD55 complex. J Biol Chem. 276:24160–24169. 2001. View Article : Google Scholar
44.	Reinhardt DP, Ono RN, Notbohm H, Muller PK, Bachinger HP and Sakai LY: Mutations in calcium-binding epidermal growth factor modules render fibrillin-1 susceptible to proteolysis. A potential disease-causing mechanism in Marfan syndrome. J Biol Chem. 275:12339–12345. 2000. View Article : Google Scholar
45.	Jaspars LH, Vos W, Aust G, Van Lier RA and Hamann J: Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens. 57:325–331. 2001. View Article : Google Scholar : PubMed/NCBI
46.	Veninga H, de Groot DM, McCloskey N, et al: CD97 antibody depletes granulocytes in mice under conditions of acute inflammation via a Fc receptor-dependent mechanism. J Leukoc Biol. 89:413–421. 2011. View Article : Google Scholar : PubMed/NCBI
47.	Wang T, Tian L, Haino M, et al: Improved antibacterial host defense and altered peripheral granulocyte homeostasis in mice lacking the adhesion class G protein receptor CD97. Infect Immun. 75:1144–1153. 2007. View Article : Google Scholar : PubMed/NCBI
48.	Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J and Spendlove I: Costimulation via CD55 on human CD4⁺ T cells mediated by CD97. J Immunol. 177:1070–1077. 2006. View Article : Google Scholar : PubMed/NCBI
49.	Abbott RJ, Spendlove I, Roversi P, et al: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem. 282:22023–22032. 2007. View Article : Google Scholar : PubMed/NCBI
50.	Li L, Spendlove I, Morgan J and Durrant LG: CD55 is over-expressed in the tumour environment. Br J Cancer. 84:80–86. 2001. View Article : Google Scholar : PubMed/NCBI
51.	MacLennan IC: Germinal centers. Annu Rev Immunol. 12:117–139. 1994. View Article : Google Scholar
52.	Groeneveld PH, Erich T and Kraal G: The differential effects of bacterial lipopolysaccharide (LPS) on splenic non-lymphoid cells demonstrated by monoclonal antibodies. Immunology. 58:285–290. 1986.
53.	Berney C, Herren S, Power CA, Gordon S, Martinez-Pomares L and Kosco-Vilbois MH: A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein. J Exp Med. 190:851–860. 1999. View Article : Google Scholar
54.	Kop EN, Kwakkenbos MJ, Teske GJ, et al: Identification of the epidermal growth factor-TM7 receptor EMR2 and its ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum. 52:442–450. 2005. View Article : Google Scholar : PubMed/NCBI
55.	Kop EN, Adriaansen J, Smeets TJ, et al: CD97 neutralisation increases resistance to collagen-induced arthritis in mice. Arthritis Res Ther. 8:R1552006. View Article : Google Scholar : PubMed/NCBI
56.	Hoek RM, de Launay D, Kop EN, et al: Deletion of either CD55 or CD97 ameliorates arthritis in mouse models. Arthritis Rheum. 62:1036–1042. 2010. View Article : Google Scholar : PubMed/NCBI
57.	Visser L, de Vos AF, Hamann J, et al: Expression of the EGF-TM7 receptor CD97 and its ligand CD55 (DAF) in multiple sclerosis. J Neuroimmunol. 132:156–163. 2002. View Article : Google Scholar : PubMed/NCBI
58.	Becker S, Wandel E, Wobus M, et al: Overexpression of CD97 in intestinal epithelial cells of transgenic mice attenuates colitis by strengthening adherens junctions. PLoS One. 5:e85072010. View Article : Google Scholar : PubMed/NCBI
59.	Wong NA and Pignatelli M: Beta-catenin - a linchpin in colorectal carcinogenesis? Am J Pathol. 160:389–401. 2002. View Article : Google Scholar : PubMed/NCBI
60.	Rivard N: Phosphatidylinositol 3-kinase: a key regulator in adherens junction formation and function. Front Biosci. 14:510–522. 2009. View Article : Google Scholar : PubMed/NCBI
61.	Mustafa T, Klonisch T, Hombach-Klonisch S, et al: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol. 24:285–294. 2004.PubMed/NCBI
62.	Han SL, Xu C, Wu XL, Li JL, Liu Z and Zeng QQ: The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma. Int J Colorectal Dis. 25:695–702. 2010. View Article : Google Scholar : PubMed/NCBI
63.	Wu J, Lei L, Wang S, Gu D and Zhang J: Immunohistochemical expression and prognostic value of CD97 and its ligand CD55 in primary gallbladder carcinoma. J Biomed Biotechnol. 2012:5876722012.PubMed/NCBI
64.	Mustafa T, Eckert A, Klonisch T, et al: Expression of the epidermal growth factor seven-transmembrane member CD97 correlates with grading and staging in human oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev. 14:108–119. 2005.PubMed/NCBI
65.	Mikesch JH, Schier K, Roetger A, Simon R, Buerger H and Brandt B: The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy. Cell Oncol. 28:223–232. 2006.PubMed/NCBI
66.	Spendlove I, Li L, Carmichael J and Durrant LG: Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res. 59:2282–2286. 1999.PubMed/NCBI
67.	Hindmarsh EJ and Marks RM: Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol. 28:1052–1062. 1998. View Article : Google Scholar
68.	Nasu J, Mizuno M, Uesu T, et al: Cytokine-stimulated release of decay-accelerating factor (DAF;CD55) from HT-29 human intestinal epithelial cells. Clin Exp Immunol. 113:379–385. 1998. View Article : Google Scholar : PubMed/NCBI
69.	Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA and Armitage NC: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother. 52:638–642. 2003. View Article : Google Scholar : PubMed/NCBI
70.	Wobus M, Vogel B, Schmucking E, Hamann J and Aust G: N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int J Cancer. 112:815–822. 2004. View Article : Google Scholar : PubMed/NCBI
71.	Safaee M, Clark AJ, Oh MC, et al: Overexpression of CD97 confers an invasive phenotype in glioblastoma cells and is associated with decreased survival of glioblastoma patients. PLoS One. 8:e627652013. View Article : Google Scholar : PubMed/NCBI
72.	Bates RC, DeLeo MJ III and Mercurio AM: The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res. 299:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
73.	Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12:375–391. 2001. View Article : Google Scholar
74.	Wobus M, Huber O, Hamann J and Aust G: CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Mol Carcinog. 45:881–886. 2006. View Article : Google Scholar : PubMed/NCBI
75.	Xu Y, Gaudette DC, Boynton JD, et al: Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res. 1:1223–1232. 1995.PubMed/NCBI
76.	Guo R, Kasbohm EA, Arora P, et al: Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology. 147:4883–4892. 2006. View Article : Google Scholar : PubMed/NCBI
77.	Kitayama J, Shida D, Sako A, et al: Over-expression of lysophosphatidic acid receptor-2 in human invasive ductal carcinoma. Breast Cancer Res. 6:R640–R646. 2004. View Article : Google Scholar : PubMed/NCBI
78.	Park JW, Zarnegar R, Kanauchi H, et al: Troglitazone, the peroxi-some proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid. 15:222–231. 2005. View Article : Google Scholar